Literature DB >> 26383519

The chemokine receptor CXCR7 is a critical regulator for the tumorigenesis and development of papillary thyroid carcinoma by inducing angiogenesis in vitro and in vivo.

Hengwei Zhang1, Lei Yang2, Xuyong Teng1, Zhangyi Liu1, Chenxi Liu1, Lei Zhang1, Zhen Liu3.   

Abstract

Papillary thyroid carcinoma (PTC) is a well-differentiated neoplasm, but it can transfer early to cervical lymph nodes. Accumulating evidences have confirmed the important roles of CXCR7 in tumor cell proliferation, invasion, metastasis, and angiogenesis. Our previous study demonstrated CXCR7 modulated proliferation, apoptosis, and invasion of PTC cells. In this study, we evaluated the effect of expression of CXCR7 in PTC cells on angiogenesis and whether its expression had an influence on the tumor growth of PTC in vivo. We evaluated the effect of CXCR7 on interleukin-8 (IL-8) and vascular endothelial growth factor (VEGF) secretion, angiogenesis, and tumor growth by ELISA, endothelial tube formation assay, and a xenograft tumor model in nude mice. Immunohistochemistry was used to assess expression of CD34 in tumor of mice. In vitro and in vivo studies in PTC cells suggested that the alteration of CXCR7 expression was correlated with angiogenesis and tumor growth. Moreover, CXCR7 mediated the expression of IL-8 and VEGF, which might be involved in the regulation of tumor angiogenesis. These findings suggest that CXCR7 affects the growth of PTC cells and participates in the tumorigenesis of PTC, probably through regulating angiogenesis by the proangiogenic VEGF or IL-8.

Entities:  

Keywords:  Angiogenesis; CXCR7; Chemokine receptor; Interleukin-8; Thyroid neoplasms; Vascular endothelial growth factor

Mesh:

Substances:

Year:  2015        PMID: 26383519     DOI: 10.1007/s13277-015-4051-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  31 in total

1.  The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes.

Authors:  Karl Balabanian; Bernard Lagane; Simona Infantino; Ken Y C Chow; Julie Harriague; Barbara Moepps; Fernando Arenzana-Seisdedos; Marcus Thelen; Françoise Bachelerie
Journal:  J Biol Chem       Date:  2005-08-17       Impact factor: 5.157

2.  High expression of CXCR7 combined with Alpha fetoprotein in hepatocellular carcinoma correlates with extra-hepatic metastasis to lung after hepatectomy.

Authors:  T C Xue; D Han; R X Chen; J H Zou; Y Wang; Z Y Tang; S L Ye
Journal:  Asian Pac J Cancer Prev       Date:  2011

3.  Role of chemokine receptor CXCR7 in bladder cancer progression.

Authors:  Mingang Hao; Jianghua Zheng; Kailin Hou; Jinglong Wang; Xiaosong Chen; Xiaojiong Lu; Junjie Bo; Chen Xu; Kunwei Shen; Jianhua Wang
Journal:  Biochem Pharmacol       Date:  2012-04-13       Impact factor: 5.858

4.  SDF-1/CXCR7 axis enhances ovarian cancer cell invasion by MMP-9 expression through p38 MAPK pathway.

Authors:  Yuecheng Yu; Hongmei Li; Baoyao Xue; Xia Jiang; Kan Huang; Junli Ge; Hongju Zhang; Biliang Chen
Journal:  DNA Cell Biol       Date:  2014-05-12       Impact factor: 3.311

5.  Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells.

Authors:  Ke Zheng; Hong-Yuan Li; Xin-Liang Su; Xiao-Yi Wang; Tian Tian; Fan Li; Guo-Sheng Ren
Journal:  J Exp Clin Cancer Res       Date:  2010-04-11

6.  Down-regulation of CXCR7 inhibits the growth and lung metastasis of human hepatocellular carcinoma cells with highly metastatic potential.

Authors:  Tong-Chun Xue; Rong-Xin Chen; Dan Han; Jie Chen; Qiong Xue; Dong-Mei Gao; Rui-Xia Sun; Zhao-You Tang; Sheng-Long Ye
Journal:  Exp Ther Med       Date:  2011-09-29       Impact factor: 2.447

7.  CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature.

Authors:  Zhenhua Miao; Kathryn E Luker; Bretton C Summers; Rob Berahovich; Mahaveer S Bhojani; Alnawaz Rehemtulla; Celina G Kleer; Jeffrey J Essner; Aidas Nasevicius; Gary D Luker; Maureen C Howard; Thomas J Schall
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-26       Impact factor: 11.205

Review 8.  Angiogenesis in cancer, vascular, rheumatoid and other disease.

Authors:  J Folkman
Journal:  Nat Med       Date:  1995-01       Impact factor: 53.440

9.  Involvement of the CXCR7/CXCR4/CXCL12 axis in the malignant progression of human neuroblastoma.

Authors:  Julie Liberman; Hervé Sartelet; Marjorie Flahaut; Annick Mühlethaler-Mottet; Aurélie Coulon; Carine Nyalendo; Gilles Vassal; Jean-Marc Joseph; Nicole Gross
Journal:  PLoS One       Date:  2012-08-20       Impact factor: 3.240

10.  C-X-C motif chemokine 12/C-X-C chemokine receptor type 7 signaling regulates breast cancer growth and metastasis by modulating the tumor microenvironment.

Authors:  Nissar Wani; Mohd W Nasser; Dinesh K Ahirwar; Helong Zhao; Zhenhua Miao; Konstantin Shilo; Ramesh K Ganju
Journal:  Breast Cancer Res       Date:  2014-05-29       Impact factor: 6.466

View more
  5 in total

Review 1.  Role of Chemokines in Thyroid Cancer Microenvironment: Is CXCL8 the Main Player?

Authors:  Mario Rotondi; Francesca Coperchini; Francesco Latrofa; Luca Chiovato
Journal:  Front Endocrinol (Lausanne)       Date:  2018-06-21       Impact factor: 5.555

2.  CXCR7 Inhibits Fibrosis via Wnt/β-Catenin Pathways during the Process of Angiogenesis in Human Umbilical Vein Endothelial Cells.

Authors:  MinQian Shen; YiFan Feng; Jing Wang; YuanZhi Yuan; Fei Yuan
Journal:  Biomed Res Int       Date:  2020-06-05       Impact factor: 3.411

Review 3.  Sex Bias in Differentiated Thyroid Cancer.

Authors:  Valentine Suteau; Mathilde Munier; Claire Briet; Patrice Rodien
Journal:  Int J Mol Sci       Date:  2021-11-30       Impact factor: 5.923

4.  Knockdown of long non-coding RNA XIST increases blood-tumor barrier permeability and inhibits glioma angiogenesis by targeting miR-137.

Authors:  H Yu; Y Xue; P Wang; X Liu; J Ma; J Zheng; Z Li; Z Li; H Cai; Y Liu
Journal:  Oncogenesis       Date:  2017-03-13       Impact factor: 7.485

5.  CXCR4/CXCR7/CXCL12-Axis in Follicular Thyroid Carcinoma.

Authors:  Thomas Artur Werner; Christina Maria Forster; Levent Dizdar; Pablo Emilio Verde; Katharina Raba; Matthias Schott; Wolfram Trudo Knoefel; Andreas Krieg
Journal:  J Cancer       Date:  2018-02-27       Impact factor: 4.207

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.